The competition between Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) for dominance of America's GLP-1 weight loss drug market is one of the most consequential pharmaceutical battles in decades, with the winner potentially capturing a market analysts project could reach $100 billion in US annual revenue by 2030.
Novo Nordisk currently leads in US market share with approximately 60% of GLP-1 prescriptions, driven by Wegovy's first-mover advantage in obesity treatment and Ozempic's massive brand recognition. But Eli Lilly's Zepbound β which showed 20.9% average weight loss in clinical trials versus 15.4% for Wegovy β is gaining ground rapidly. Lilly has outpaced Novo Nordisk in US prescriptions for the past four consecutive months.
The competition is driving beneficial outcomes for American patients. Prices have begun falling as both companies seek market share. Eli Lilly launched a $25/week direct-to-consumer version through its LillyDirect platform, bypassing insurance and pharmacy benefit managers entirely. Novo Nordisk responded with its own direct pricing program.
The next frontier is oral formulations. Both companies have oral GLP-1 pills in late-stage clinical trials. An effective daily pill at reasonable cost would expand the addressable US market by an estimated 40 million patients who prefer oral to injectable medication.
